about
Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's diseaseTranscriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic OpportunitiesPharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of actionSTEP levels are unchanged in pre-frontal cortex and associative striatum in post-mortem human brain samples from subjects with schizophrenia, bipolar disorder and major depressive disorderMicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function.Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder.Downstream effects of striatal-enriched protein tyrosine phosphatase reduction on RNA expression in vivo and in vitro.A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing.Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma.Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease.Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies.Behavioral characterization of striatal-enriched protein tyrosine phosphatase (STEP) knockout mice.Interactome analysis reveals ZNF804A, a schizophrenia risk gene, as a novel component of protein translational machinery critical for embryonic neurodevelopment.Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain.Factors influencing metabolic rate in naked mole-rats (Heterocephalus glaber).Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury.LRRK2 activation in idiopathic Parkinson's disease.In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesisH2 histaminergic control of inhibition of eating induced by intragastric NaCl in ratsDysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophreniaGluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons
P50
Q27676406-7678D130-C94C-470E-BA11-9D7B14349742Q27703135-EC85816E-C89B-4A1C-9ED7-1D0B9E3B09D4Q33549121-F3A2EA30-666E-417F-8FA4-F6812B172CA7Q34249424-23F7DA50-AF9F-4990-B1D2-A9B6C82E34D8Q35191367-F52CC62A-F67E-4C00-8002-28A62E70AC99Q35779169-6FCC1703-FCCE-44A7-BA97-780EEFB2E542Q40036225-8DBF851B-AEED-454D-A330-B8A820622FAAQ40241539-EAE8F497-2DC1-4EF4-B408-ADC613593DBAQ41183343-ECAE2540-8EA8-4366-AB45-D1F928AD7D63Q42677703-894B479F-99CC-458B-A5E6-D732179C2BDFQ42753490-7145C53C-E1AB-48F5-8C57-ADCE9B67DE3AQ42754596-B5CC0D66-08CC-47FE-9050-9D3C0F80F0E2Q44355481-BDF01683-C50B-4BD9-9299-4F8552AAA2D7Q44669549-3DC14242-843C-44C6-A8B8-18B479BCD7A2Q44725362-C65BB06E-0586-4975-AEB0-7539DE1DD441Q45038737-09986D97-7FEF-4CC9-ABC6-029CEE462786Q45299993-11E77AE2-546C-4BAE-85A8-CF502C601A30Q46197559-4DD1B3EB-983F-4B7E-86CB-BD8CB5D4BBC3Q46832736-988EF446-581C-4E91-8657-21E6AA2D2C7FQ47741961-368B552E-6147-4038-BDD3-900F49A56B20Q47781553-61978F7E-31B5-4978-83E2-F559CF6E938AQ48553009-D191D4FB-33CE-4666-82A2-4F7651041FDBQ51456617-37A7D3BE-C0BB-4FD1-BA4F-141450D878DCQ54212364-3D396B12-ED07-446E-BB1E-87D6325F9533Q60143544-D906F08F-C99E-4B7C-BF2A-FE3CD3EB0D3CQ60143545-CD33030B-45C9-47C2-99D8-92E1F8DE7AE0Q60143548-CA479DC1-5BA3-49AF-8042-FD2D62D8FC5AQ91142967-768549CA-6B7F-4482-9F47-12A8E2FD8F16Q96121271-1BD991FE-0732-4FFD-BBDB-F7F016F140CB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas A. Lanz
@ast
Thomas A. Lanz
@en
Thomas A. Lanz
@es
Thomas A. Lanz
@nl
Thomas A. Lanz
@sl
type
label
Thomas A. Lanz
@ast
Thomas A. Lanz
@en
Thomas A. Lanz
@es
Thomas A. Lanz
@nl
Thomas A. Lanz
@sl
prefLabel
Thomas A. Lanz
@ast
Thomas A. Lanz
@en
Thomas A. Lanz
@es
Thomas A. Lanz
@nl
Thomas A. Lanz
@sl
P106
P108
P1153
7006579361
P21
P31
P496
0000-0003-2483-3122